Document is current
Any future updates will be listed below
-
Authors
Muradova, Zeinaf
Carmès, Léna
Brown, Needa
Rossetti, Fabien
Guthier, Romy
Yasmin-Karim, Sayeda
Lavelle, Michael
Morris, Toby
Guidelli, Eder Jose
Isikawa, Mileni
Dufort, Sandrine
Bort, Guillaume
Tillement, Olivier
Lux, François
Berbeco, Ross
-
Funding
Funding for this research was provided by:
National Cancer Institute (R01CA240804)
National Cancer Institute (R01CA240804)
National Cancer Institute (R01CA240804)
National Cancer Institute (R01CA240804)
National Cancer Institute (R01CA240804)
National Cancer Institute (R01CA240804)
National Cancer Institute (R01CA240804)
CNRS (IRP radioboost)
CNRS (IRP radioboost)
CNRS (IRP radioboost)
CNRS (IRP radioboost)
CNRS (IRP radioboost)
CNRS (IRP radioboost)
- License Information
-
More Information
Article History
Received: 21 January 2025
Accepted: 11 June 2025
First Online: 1 July 2025
Change Date: 31 July 2025
Change Type: Update
Change Details: The original online version of this article has been revised: ESM has been updated.
Declarations
:
: All animal experiments complied with the requirements of the Dana Farber Cancer Institute (DFCI) Institutional Animal Care and Use Committee (IACUC, Protocol Number 14–032) and were conducted in full compliance with the guidelines and regulations set by the Association for the Assessment and Accreditation of Laboratory Animal Care in the United States Public Health Service Guide.
: All authors concur with the submission and publication of this paper.
: François Lux and Olivier Tillement disclose the patent WO2011/135101. François Lux, Olivier Tillement, and Ross Berbeco disclose the patent US62431607. Léna Carmès and Sandrine Dufort are employees of NH TherAguix which develops AGuIX® nanoparticles. François Lux, Olivier Tillement and Sandrine Dufort have shares in this company.
